Cytokines and statin therapy in chronic obstructive pulmonary disease patients

References

• GOLD. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. [Internet]. 2017 [cited 2017 Apr 25]. Available from: www.gold.org
   Google Scholar
• Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33:1165–1185.
   PubMed Web of Science ®Google Scholar
• Chatila WM, Thomashow BM, Minai OA, et al. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5:549–555.
   PubMedGoogle Scholar
• MacNee W. Systemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary disease. Ann Med. 2013;45:291–300.
   PubMed Web of Science ®Google Scholar
• Faner R, Tal-Singer R, Riley JH, et al. Lessons from ECLIPSE: a review of COPD biomarkers. Thorax. 2014;69:666–672.
   PubMed Web of Science ®Google Scholar
• Agusti A, Sin DD. Biomarkers in COPD. Clin Chest Med. 2014;35:131–141.
   PubMed Web of Science ®Google Scholar
• Atamas SP, Chapoval SP, Keegan AD. Cytokines in chronic respiratory diseases. F1000 Biol Rep. 2013;5:3.
   PubMedGoogle Scholar
• Chung KF. Cytokines in chronic obstructive pulmonary disease. Eur Respir J. 2001;18:50–59.
   Web of Science ®Google Scholar
• Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest. 2008;118:3546–3556.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. The cytokine network in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2009;41:631–638.
   PubMed Web of Science ®Google Scholar
• Caramori G, Adcock IM, Di Stefano A, et al. Cytokine inhibition in the treatment of COPD. Int J Chron Obstruct Pulmon Dis. 2014;9:397–412.
   PubMed Web of Science ®Google Scholar
• Selvarajah S, Todd I, Tighe PJ, et al. Multiple circulating cytokines are coelevated in chronic obstructive pulmonary disease. Mediators Inflamm. 2016;2016:1.
   Google Scholar
• Miller J, Edwards LD, Agusti A, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med. 2013;107:1376–1384.
   PubMed Web of Science ®Google Scholar
• El-Shimy W, El-Dib A, Nagy H, et al. A study of IL-6, IL-8, and TNF-α αs inflammatory markers in COPD patients. Egypt J Bronchol. 2014;8:91.
   Google Scholar
• Wouters EFM, Groenewegen KH, Dentener MA, et al. Systemic inflammation in chronic obstructive pulmonary disease: the role of exacerbations. Proc Am Thorac Soc. 2007;4:626–634.
   PubMedGoogle Scholar
• Perret J, Mcdonald C, Apostolopoulos V. Elevated serum interleukin-5 levels in severe chronic obstructive pulmonary disease. 2017;49:1–4.
   Google Scholar
• Chung KF. Cytokines. In: Barnes PJ, Drazen JM, Rennard SI, Thomson NC, editors. Asthma COPD Basic Mech Clinical Manag Second Edi. New York, USA: Elsevier Ltd; 2009. p. 327–341.
   Google Scholar
• Dobler CC, Wong KK, Marks GB. Associations between statins and COPD: a systematic review. BMC Pulm Med. 2009;9:32.
   PubMedGoogle Scholar
• Maneechotesuwan K, Wongkajornsilp A, Adcock IM, et al. Simvastatin suppresses airway IL-17 and upregulates IL-10 in patients with stable COPD. Chest. 2015;148:1164–1176.
   PubMed Web of Science ®Google Scholar
• Lahousse L, Loth DW, Joos GF, et al. Statins, systemic inflammation and risk of death in COPD: The Rotterdam study. Pulm Pharmacol Ther. 2013;26:212–217.
   PubMed Web of Science ®Google Scholar
• Iwata A, Shirai R, Ishii H, et al. Inhibitory effect of statins on inflammatory cytokine production from human bronchial epithelial cells. Clin Exp Immunol. 2012;168:234–240.
   PubMed Web of Science ®Google Scholar
• Pinto-Plata V, Casanova C, Müllerova H, et al. Inflammatory and repair serum biomarker pattern. Association to clinical outcomes in COPD. Respir Res. 2012;13:71.
   PubMed Web of Science ®Google Scholar
• Karadag F, Kirdar S, Karul AB, et al. The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease. Eur J Intern Med. 2008;19:104–108.
   PubMed Web of Science ®Google Scholar
• Kolsum U, Roy K, Starkey C, et al. The repeatability of interleukin-6, tumor necrosis factor-alpha, and C-reactive protein in COPD patients over one year. Int J Chron Obstruct Pulmon Dis. 2009;4:149–156.
   PubMedGoogle Scholar
• Dickens JA, Miller BE, Edwards LD, et al. COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res. 2011;12:146.
   PubMed Web of Science ®Google Scholar
• Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res. 2017;120:229–243.
   PubMed Web of Science ®Google Scholar
• Tousoulis D, Psarros C, Demosthenous M, et al. Innate and adaptive inflammation as a therapeutic target in vascular disease: the emerging role of statins. J Am Coll Cardiol. 2014;63:2491–2502.
   PubMed Web of Science ®Google Scholar
• Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89–118.
   PubMed Web of Science ®Google Scholar
• Carlson AA, Smith EA, Reid DJ. The stats are in: an update on statin use in COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:2277–2284.
   PubMed Web of Science ®Google Scholar
• Criner GJ, Connett JE, Aaron SD, et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med. 2014;370:2201–2210.
   PubMed Web of Science ®Google Scholar
• Lyngdoh T, Vollenweider P, Waeber G, et al. Association of statins with inflammatory cytokines: a population-based Colaus study. Atherosclerosis. 2011;219:253–258.
   PubMed Web of Science ®Google Scholar
• Musial J, Undas A, Gajewski P, et al. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol. 2001;77:247–253.
   PubMed Web of Science ®Google Scholar
• Koo H, Kang HK, Song P, et al. Systemic white blood cell count as a biomarker associated with severity of chronic obstructive lung disease. Tuberc Respir Dis (Seoul). 2017;80:304–310.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Nakamura H, Minematsu N, et al. Plasma cytokine profiles related to smoking-sensitivity and phenotypes of chronic obstructive pulmonary disease. Biomarkers. 2014;19:368–377.
   PubMed Web of Science ®Google Scholar
• Mosevoll KA, Skrede S, Lunde Markussen D, et al. Inflammatory mediator profiles differ in sepsis patients with and without bacteremia. Front Immunol. 2018;9:691.
   PubMed Web of Science ®Google Scholar